Compare EFOR & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOR | AURA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.5M | 713.4M |
| IPO Year | N/A | 2021 |
| Metric | EFOR | AURA |
|---|---|---|
| Price | $30.56 | $7.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.1M | 458.6K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.90 | $4.73 |
| 52 Week High | $30.71 | $9.54 |
| Indicator | EFOR | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 79.46 | 51.53 |
| Support Level | $16.94 | $6.61 |
| Resistance Level | N/A | $7.31 |
| Average True Range (ATR) | 1.54 | 0.25 |
| MACD | 1.13 | 0.00 |
| Stochastic Oscillator | 89.86 | 60.00 |
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.